Hormone replacement therapy and cardiovascular disease: Increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease

Journal of Internal Medicine

Volumn 256, Issue 5, 2004, Pages 361-374

  Lowe, Gordon D O ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Coagulation; Coronary heart disease; Hormone replacement therapy; Stroke; Venous thrombosis

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGED; BLOOD CLOTTING; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY RISK; DOCTOR PATIENT RELATION; DRUG INDUSTRY; ENDOMETRIUM CANCER; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FEMUR FRACTURE; FIBRINOLYSIS; HEALTH PROMOTION; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MASS MEDIUM; MEDICAL PRACTICE; MENOPAUSAL SYNDROME; ORAL CONTRACEPTION; OVARY CANCER; PERIPHERAL VASCULAR DISEASE; POLITICS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

BLOOD COAGULATION DISORDERS; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; FEMALE; FORECASTING; HORMONE REPLACEMENT THERAPY; HUMANS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 7244226589     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2004.01400.x     Document Type: Review

References (147)

1. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332: 1758-66.
2. Lowe GDO. Blood rheology, haemostasis and vascular disease. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds. Haemostasis and Thrombosis 3rd edn. Edinburgh: Churchill Livingstone, 1994: 1169-88.
3. Herrington DM, Espeland MA, Crouse JR III et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol 2001; 21: 1955-61.
4. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet 1998; 351: 1425-7.
5. Lawlor DA, Ebrahim S, Davey-Smith G. Role of endogenous oestrogen in aetiology of coronary heart disease. BMJ 2002; 325: 311-2.
6. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2001; CD002978.
7. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality of life and depressive symptoms in post menopausal women receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002; 287: 591-7.
8. Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, Kohrt WM. Bone mineral density response to estrogen replacement in frail elderly women: a randomised controlled trial. JAMA 2001; 286: 815-20.
9. Doren M, Samsioe G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995. Hum Reprod Update 2000; 6: 419-26.
10. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 942-4.
11. Torgerson DJ, Bell-Seyer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomised trials. JAMA 2001; 285: 2891-7.
12. Michaelsson K, Baron JA, Farahmand BY et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. Br Med J 1988; 316: 1858-63.
13. Wilson RA. Feminine Forever. New York: M Evans and Company Inc., 1966.
14. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981; i: 858-60.
15. Bush TL, Cowan LD, Barrett-Connor E et al. Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-up Study. JAMA 1983; 249: 903-6.
16. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985; 313: 1044-9.
17. Psaty BM, Heckbert SR, Atkins D et al. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med 1993; 153: 1421-7.
18. Hemminki E, Sihvo S. A review of postmenopausal hormone therapy recommendations: potential for selection bias. Obstet Gynecol 1993; 82: 1021-8.
19. Hemminki E, Malin M, Topo P. Selection to postmenopausal therapy by women's characteristics. J Clin Epidemiol 1993; 46: 211-9.
20. Lee AJ, Lowe GDO, Smith WCS, Tunstall-Pedoe H. Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy. Br J Haematol 1993; 83: 616-21.
21. Posthuma WF, Westendorp RG, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ 1994; 308: 1268-9.
22. Boston Collaborative Drug Surveillance Program. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumours in relation to postmenopausal estrogen therapy. N Engl J Med 1974; 290: 15-9.
23. Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979; 242: 1150-4.
24. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy: II. A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74-9.
25. Hammond CB, Jelovesh FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy: I. Metabolic effects. Am J Obstet Gynecol 1979; 133: 525-36.
26. Quinn DA, Thompson BT, Terrin ML et al. A prospective investigation of pulmonary embolism in women and men. JAMA 1992; 268: 1689-96.
27. Devor M, Barrett-Coimor E, Renvall M, Feigal DJ, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-82.
28. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199-208.
29. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
30. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-3.
31. Grodstein F, Stampfer MJ, Goldhaber SZ et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7.
32. Daly E, Vessey MP, Painter R, Hawkins MM. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 1996; 348: 1027.
33. Perez Gutthann S, Garcia-Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and the risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796-800.
34. Varas-Lorenzo C, Garcia-Rodriguez L, Cattaruzzi C, Troncon M, Agostinis L, Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalisation for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 1998; 147: 387-90,
35. Grady D, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA 1997; 278: 477.
36. Hulley S, Grady D, Bush T et al. Postmenopausal hormone for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomised trial of oestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
37. Grady D, Wenger NK, Herrington D et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Am Intern Med 2000; 132: 689-96.
38. Hoibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism: a population-based case-control study. Thromb Haemost 1999; 82: 1218-21.
39. Herrington DM, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-9.
40. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomised, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 961-7.
41. Viscoli CM, Brass LM, Kerran WN, Farrell PM, Fuissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischaemic stroke. N Engl J Med 2001; 345: 1243-49.
42. The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo-controlled trial. Lancet 2002; 360: 2001-8.
43. Rossouw JE, Anderson GL, Prentice RL et al. (Writing Group for the Women's Health Initiative Investigators). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA 2002; 288: 321-33.
44. Scarabin P-Y, Oger E, Flu-Bureau G, on behalf of the Estrogen and ThromboEmbolism Risk (ESTHER) Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-32.
45. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomised Controlled Trial. JAMA 2004; 291: 1701-12.
46. Hoibraaten E. Hormone replacement therapy and risk of venous thromboembolism. Thesis, University of Oslo, 2001 (ISBN 82-499-008-2).
47. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981; 305: 612-8.
48. Rosendaal FR, van Hylckama-Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003; 1: 1371-80.
49. Young RL, Goepfert AR, Foldzieher HW. Estrogen replacement therapy is not conducive of venous thromboembolism. Maturitas 1991; 13: 189-92.
50. Oger E, Scarabin PY. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Drugs Aging 1999; 14: 55-61,
51. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med 2002; 136: 680-90.
52. Gray LJ, Bath PMW. The effect of hormone replacement therapy on stroke risk, type and outcome: a systematic review of data from randomised controlled trials. Cerebrovasc Dis 2004; 17 (Suppl. 5): 18.
53. Bloemenkamp KWM, Rosendaal FR, Heimerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160: 49-52.
54. Lowe GDO, Woodward M, Vessey MP, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years: relationships to hormone replacement therapy. Thromb Haemost 2000; 83: 530-5.
55. UK Committee on Safety of Medicines and Medicines and Healthcare products Regulatory Agency. HRT: update on the risk of breast cancer and long-term safety. Curr Probl Pharmacovigilance 2003; 29: 1-3
56. Rosendaal FR, Vessey M, Rumley A et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116: 851-4.
57. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
58. Herrington DM, Vittinghoff E, Howard RD et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002; 22: 1012-17.
59. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-73.
60. Lowe GDO. Haemostatic factors in vascular disease. In: Greer I, Ginsberg J, Forbes CD, eds. Women's Vascular Health. London: Arnold, 2004 (in press).
61. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-26.
62. Lowe GDO, Rumley A, Woodward M, Reid E. Oral contraceptives and venous thromboembolism. Lancet 1997; 349: 1623 (letter).
63. Lowe GDO, Rumley A, Woodward M, Reid E, Rumley J. Activated protein C resistance and the FV: R506Q mutation in a random population sample: associations with cardiovascular risk factors and coagulation variables. Thromb Haemost 1999; 81: 918-24.
64. Rosendaal FR, Heimerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001; 86: 112-23.
65. Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE. Effects of second and third generation oral contraceptives and their respective progestogens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost 2002; 87: 199-205.
66. Stanwell-Smith R, Meade TW. Hormone replacement therapy for menopausal women: a review of its effects on haemostatic function, lipids, and blood pressure. Adv Drug React Ac Pois Rev 1984; 4: 187-210.
67. Winkler UH. Menopause, hormone replacement therapy and cardiovascular disease: a review of haemostaseological findings. Fibrinolysis 1992; 6 (Suppl. 3): 5-10.
68. Meade TW. Hormone replacement therapy and haemostatic function. Thromb Haemost 1997; 78: 765-9.
69. Thijs A, Stehouwer CDA. Changes of hemostatic variables during hormone replacement therapy. Semin Vasc Med 2003; 3: 85-92.
70. Nabulsi AA, Folsom AR, White A et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-75.
71. Medical Research Council, General Practice Research Framework. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. BMJ 1996; 213: 473-8.
72. Whiteman MK, Cui Y, Flaurs JA, Espeland M, Bush TL. Low fibrinogen level: a predisposing factor for venous thromboembolic events with hormone replacement therapy. Am J Hematol 1999; 61: 271-3.
73. Lowe GDO, Upton MN, Rumley A, McConnachie A, O'Reilly DSJ, Watt GCM. Different effect of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein: a cross-sectional population survey. Thromb Haemost 2001; 86: 550-6.
74. Tsai AW, Cushman M, Rosamond WD et al. Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med 2002; 113: 636-42.
75. van Hylckama Vleig A, van der Linden I, Bertina RM, Rosendaal FR. High levels of factor IX and venous thrombosis. Blood 2000; 95: 3678-82.
76. Lowe GDO. Factor IX and thrombosis. Br J Haematol 2001; 115: 507-13.
77. Sporrong T, Mattsson LA, Samsioe G, Stigendal L, Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol 1990; 97: 939-44.
78. Caine YG, Bauer KA, Barzegar S et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992; 68: 392-392.
79. Scarabin PY, Alhenc-Gelas M, Flu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomised controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-8.
80. Bonduki CE, Lourenco DM, Baracat E et al. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women. Acta Obstet Gynecol Scand 1998; 77: 330-3.
81. Hahn L, Mattsson L-A, Andersson B, Tengborn L. The effects of oestrogen replacement therapy on haemostatic variables in postmenopausal women with non-insulin-dependent diabetes mellitus. Blood Coagul Fibrinolysis 1999; 10: 81-6.
82. van Baal WM, Emeis JJ, van der Mooren MJ et al. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 2000; 83: 29-34.
83. Hoibraaten E, Os I, Seljeflot I et al. The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study. Thromb Res 2000; 98: 19-27.
84. Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomised, double-blind, placebo-controlled trial. Br J Haematol 2001; 115: 415-20.
85. Hoibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism - results from a randomised, double-blind, clinical trial. Thromb Haemost 2001; 85: 775-81.
86. Koh KK, Ahun JY, Kim DS et al. Effect of hormone replacement therapy on tissue factor activity, C-reactive protein, and the tissue factor pathway inhibitor. Am J Cardiol 2003; 91: 371-3.
87. Gilabert J, Estelles A, Cano A et al. The effect of estrogen replacement therapy with or without progestogen on the flbrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 1995; 173: 1849-54.
88. Sidelmann JJ, Jespersen J, Andersen LF, Skouby SO. Hormone replacement therapy and hypercoagulability. Results from the Prospective Danish Climacteric Study. Br J Obstet Gynaecol 2003; 110: 541-7.
89. Gottsater A, Rendell M, Hultehn UL, Berntorp E, Mattiason I. Hormone replacement therapy in healthy postmenopausal women: a randomised, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Intern Med 2001; 249: 237-46.
90. Peverill RE, Teede HJ, Smolich JJ et al. Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII. Clin Sci 2001; 101: 93-9.
91. Luyer MD, Khosla S, Owen WG, Miller VM. Prospective randomised study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 2001; 86: 3629-34.
92. Bladbjerg EM, Madsen JS, Kristensen SR et al. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin-activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomised controlled study. J Thromb Haemost 2003; 1: 1208-14.
93. Folsom AR, Aleksic N, Wang L, Cushman M, Wu KK, White RH. Protein C, antithrombin, and venous thromboembolism incidence. A prospective population-based study. Arteriosder Thromb Vasc Biol 2002; 22: 1018-22.
94. Vandenbroucke JP, Heimerhorst FM. Risk of venous thrombosis with hormone-replacement therapy. Lancet 1996; 348: 972.
95. Post MS, Rosing J, Van Der Mooren MJ et al. Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy postmenopausal women. Br J Haematol 2002; 119: 1017-23.
96. Marcucci R, Abbate R, Fedi S et al. Acquired activated protein C resistance in postmenopausal women is dependent on factor VIIIc levels. Am J Clin Pathol 1999; 111: 769-72.
97. Koh KK, Mincemoyer R, Bui MN et al. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683-90.
98. Teede HJ, McGrath BP, Smolich JJ et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000; 20: 1404-9.
99. Vehkavarra S, Silveira A, Hakala-Ala-Pietila T et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619-25.
100. Astrup T. The haemostatic balance. Thromb Diath Haemorrh (Stutt) 1958; 2: 347-57.
101. Folsom AR, Cushman M, Heckbert SR, Rosamond WD, Aleksic N. A prospective study of ftbrinolytic markers and venous thromboembolism. J Clin Epidemiol 2003; 56: 598-603.
102. Lowe GDO. Prediction of postoperative deep vein thrombosis. Thromb Haemost 1997; 78: 47-52.
103. Lowe GDO, Haverkate F, Thompson SG et al., on behalf of the ECAT DVT Study Group. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. Thromb Haemost 1999; 81: 879-86.
104. Ridker PM, Vaughan DE, Stampfer MJ et al. Baseline flbrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator inhibitor. Circulation 1992; 85: 1822-7.
105. Crowther MA, Roberts J, Roberts R et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost 2001; 85: 390-4.
106. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
107. van Baal WM, Kenemans P, van der Mooren M, Kessel H, Emeis J, Stehouwer CDA. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999; 81: 925-8.
108. Cushman M, Legault C, Barrett-Connor E et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 717-22.
109. Cushman M, Meilahn EN, Psaty BM et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arteriosder Thromb Vasc Biol 1999; 19: 893-9.
110. Zegura B, Keber I, Sebestjen M, Koenig W. Double-blind, randomised study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 2003; 168: 123-9.
111. Lowe GDO, Rumley A, Woodward M, Vessey M. C-reactive protein, idiopathic venous thrombo-embolism and hormone replacement therapy. Thromb Haemost 2000; 84: 730-41.
112. Fox J, George AJ, Newton JR et al. Effect of transdermal oestradiol on the haemostatic balance of menopausal women. Maturitas 1993; 18: 55-64.
113. The Writing Group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxy-progesterone acetate: a 1-year, double-blind, placebo-controlled study. Thromb Haemost 1996; 75: 476-80.
114. Grady D, Herrington D, Bittner V et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 2002; 288: 49-57.
115. Manson JE, Hsia J, Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-34.
116. Wassertheil-Smoller S, Hendrix SL, Limacher M et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomised trial. JAMA 2003; 289: 2673-84.
117. Clarke SC, Kelleher J, Lloyd-Jones H et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study. Br J Obstet Gynaecol 2002; 109: 1056-62.
118. Coull AJ, Rothwell PM. What proportion of all acute vascular events in the population are cerebrovascular? Implications for funding of clinical services and research. Cerebrovasc Dis 2004; 17 (Suppl. 5): 21.
119. Hsai J, Criqui MH, Rodabough RJ et al. Estrogen plus progestin and the risk of peripheral arterial disease. The Women's Health Initiative. Circulation 2004; 109: 620-26.
120. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003; 348: 645-50.
121. Hodis HN, Mack WJ, Azen SP et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003; 349: 535-45.
122. Grodstein F, Manson JE, Colditz GA et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-4.
123. Lowe GDO, Rumley A, Whincup PH, Danesh J. Hemostatic and rheological variables and risk of cardiovascular disease. Semin Vasc Med 2002; 2: 429-40.
124. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146: 948-57.
125. Psaty BM, Smith NL, Lemaitre RN et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident non-fatal myocardial infarction. JAMA 2001; 285: 906-13.
126. Lemaitre RN, Psaty BM, Heckbert SR, Smith NL, Longstreth WT Jr, Rosendaal FR. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal ischemic stroke in postmenopausal women. Arterioscler Thromb Vasc Biol 2002; 22: 1051-2.
127. Reiner AP, Heckbert SH, Vos HL et al. Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of non-fatal myocardial infarction. Blood 2003; 102: 25-30.
128. Koenig W, Rosenson RS. Acute-phase reactants and coronary disease. Semin Vasc Med 2002; 2: 417-28.
129. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
130. Scottish Intercollegiate Guidelines Network (SIGN). Prophylaxis of Venous Thromboembolism (SIGN Guideline 62). Edinburgh: SIGN 2002 (accessible at http://www.sign. ac.uk, 16/9/04).
131. Greer IA, Walker ID. Hormone Replacement Therapy and Venous Thromboembolism. London: Royal College of Obstetricians and Gynaecologists (RCOG Guideline 19), 2004.
132. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003; 10 (Suppl 1): S1-S78.
133. Mosca L, Appel LJ, Benjamin EJ et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004; 109: 673-93.
134. Royal College of Physicians of Edinburgh. Consensus Conference on Hormone Replacement Therapy: Consensus Statement. Edinburgh: RCPE 2003 (accessible at http:// www.rcpe.ac.uk. 16/9/04).
135. Hulley SB, Grade D. The WHI estrogen-alone trial - do things look any better? JAMA 2004; 291: 1769-71.
136. Scottish Intercollegiate Guidelines Network (SIGN). Management of Osteoporosis (SIGN Guideline 71). Edinburgh: SIGN 2003 (accessible at http://www.sign.ac.uk. 16/9/04).
137. Cranney A, Guyatt G, Griffith L et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrinol Rev 2002; 23: 570-78.
138. UK Medicines and Healthcare Products Regulatory Agency. 2003 (accessible at http://www.medicines.mhra.gov.uk, 16/9/04).
139. Singh D. HRT no longer first choice for preventing osteoporosis. BMJ 2003; 327: 1364.
140. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 289: 2189-97.
141. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 1371-88.
142. Koh KK, Ahn JY, Jin DK et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1889-94.
143. Lagro-Janssen T, Rosser WW, van Weel C. Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces. Lancet 2003; 362: 414-5.
144. Hemminki E, McPherson K. Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease. Lancet 2000; 355: 566-69.
145. Lexchin J. Clinical trials register. Lancet 2004; 364: 330.
146. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004; 291: 47-53.
147. Huntingford CA. Confusion over benefits of hormone replacement therapy. Lancet 2004; 363: 332.